甘李药业甘精胰岛素注射液等获埃塞俄比亚药品注册批件

Core Viewpoint - Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, marking a significant milestone for the company in expanding its market presence in the region [1]. Company Summary - Ganli Pharmaceutical (603087) announced on January 15 that it has obtained the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1]. - The approved Glargine Insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a sustained hypoglycemic effect for 24 hours [1]. - The characteristics of Glargine Insulin include a long duration of action, stable blood concentration without peaks, and smooth glucose control [1].